After loading STV-C8 with components of the CRISPR/Cas9 system and injecting it into the muscle of a pig, the team succeeded in removing a disease-relevant section of the dystrophin gene, which encodes a protein that stabilizes muscle cells and is disrupted in Duchenne muscular dystrophy. ^[1] In 2026, researchers at the Institute of Stem Cell Research (ISF) and the Institute of Developmental Genetics (IDG) at Helmholtz Munich and the Technical University of Munich constructed an RNA transporter called STV-C8 from the ground up, combining functional protein building blocks with a structural protein designed using generative AI. ^[2][3] In cell culture, STV-C8 delivered RNA into target cells far more efficiently than virus-like particles and lipid nanoparticles, achieving a substantially higher transfection rate and requiring substantially less RNA for comparable protein production. ^[4][7] Prof. Wolfgang Wurst, Emeritus of Excellence at Helmholtz Munich and TUM and last author of the Nature publication, said the team plans to transfer the STV-C8 technology into a spin-off company. ^[5] In animal models, intravenous administration of STV-C8 in mice led to expression of the delivered RNA primarily in the lungs, with no evidence of immunological or toxic side effects. ^[6]